Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
This is a retrospective observational study aimed at describing the characteristics and
outcome of CLL patients included in the NPP in Italy in a period of time ranging from the
start of the NPP until November, 30th 2014. A longitudinal survey will be carried out by
collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be
observed for at least 12 months from the treatment start.